Market Size (2017)
—
Market Research ReportStandard
Viral Vector Manufacturing Market
By Segment, By Region, And Segment Forecasts, 2015 – 2023
Vertical: HealthcareBase Year: 2017
Vertical: HealthcareBase Year: 2017
Market Size (2017)
—
Projected (2023)
—
CAGR (2015–2023)
N/A
Key Players
10+
This report covers Viral Vector Manufacturing Market with forecasts from 2015 to 2023. 10 key companies are profiled.
Viral Vector Manufacturing Market is a key focus area for market intelligence and strategic research.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansViral vectors are tools usually used by molecular biologists to deliver genetic materials into cells. Viral vector manufacturing refers to the production of a carrier called a vector which is genetically engineered to deliver the gene as it delivers the new gene by infecting the cell. Considered as a drug substance, viral vectors are used in gene therapy and vaccinology (vaccines). Viral vectors used in gene therapy mostly include adenovirus, retrovirus, and adeno-associated viral (AAV). Viruses that are often used as vectors include retroviruses that integrate their genetic material including the new gene in the human cell and adenoviruses which introduce their deoxyribonucleic acid (DNA) into the nucleus of the cell without letting the DNA to integrate into a chromosome. In this study, we have also considered the services involved in the manufacturing of viral vectors.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans1.1 Research Process
Wantstats research is conducted by industry experts who offer insight into industry structure, market segmentation, assessment, competitive landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Primary Research
Extensive primary research was conducted to gain a deeper insight into the market and industry performance. In this report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed over the next five to ten years.
Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global viral vector manufacturing market. It was also used to obtain key information about major market players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources such as World Health Organization (WHO), US Department of Health and Human Services (HHS), US Food and Drug Administration (FDA), National Health Expenditure Accounts (NHEA), International Agency for Research on Cancer (IARC), National Center for Biotechnology Information (NCBI), Familial Hypercholesterolemia (FH) Foundation, United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), Partnership to Fight Chronic Disease (PFCD), Agency for Healthcare Research and Quality (AHRQ), European Commission (EC), World Bank, China National Cancer Center, Organization for Economic Cooperation and Development (OECD), Pharmaceutical Research and Manufacturers of America (PhRMA), Central Bureau of Health Intelligence (CBHI), Ministry of Health, Labor, and Welfare Japan, World Cancer Research Fund International (WCRF International), Korean Cancer Association, expert interviews, Wantstats analysis, annual reports, SEC filings, journals, white papers, corporate presentations, company websites, some paid databases, and many others.
Market Size Estimation
Both, top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent submarkets of the overall global viral vector manufacturing market. The key players in the market were identified through secondary research, and their market contributions in the respective geographies were determined through primary and secondary research. This entire procedure included the study of the annual and financial reports of top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market have been covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data has been consolidated and added with detailed inputs and analysis from Wantstats and has been presented in this report. The following figure shows an illustrative representation of the overall market size estimation process employed for this study.
Base Year
2017
Historical Period
2015 – 2016
Forecast Period
2018 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Introduction
A large number of companies are working in the global viral vector manufacturing market. Through extensive research, it is found that market players have adopted strategies such as product launches and collaborations. On the basis of market study, we found some key players operating in this market which are Lonza, Merck KGaA, Cobra Biologics, Oxford BioMedica, Spark Therapeutics, Inc., FinVector Vision Therapies, FUJIFILM Diosynth Biotechnologies U.S.A., Inc.,Brammer Bio, uniQure N.V.,Novasep, and others.
Many leading players are concentrated in the Americas and Europe owing to the rising awareness of gene therapies and the importance of viral vector manufacturing products, well-established markets, high healthcare expenditures, and numerous opportunities for growth. These companies have expanded their market in other regions as well. Major players in the market are investing a huge amount of money in research and development activities to launch better and cost-effective products in the viral vector manufacturing market. They are also focusing on expanding their geographical boundaries by launching new products in emerging markets of developing countries.
Furthermore, companies such as Lonza, Merck KGaA, and Oxford BioMedica are major players in the market. Apart from this, Cobra Biologics, Spark Therapeutics, Inc., FinVector Vision Therapies, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Brammer Bio, and uniQure N.V., Novasep are some of the well-established players in the global viral vector manufacturing market.
Lonza ranks first in the global viral vector manufacturing market. The company is one of the most trusted biopharmaceutical brands in the world. Amongst the viral vector manufacturing products, the company manufacturers adeno-associated viral (AAV) vectors, adenoviral vectors, lentiviral vectors, retroviral vectors, live viruses, and attenuated viruses. It has a strong distribution network in more than 100 countries and a research and development team to innovate new products in the market.
Merck KGaA is the second largest in the global viral vector manufacturing market. The company is a major player in the global pharmaceuticals market and operates in business segments, namely, healthcare, life sciences, and performance materials. The company is present in more than 180 counties and offers around 300000 products. It provides cell culture supplements, prefiltration, bioburden reduction, bioreactor, and other products for manufacturing viral vectors.
Oxford BioMedica is the third largest in the global viral vector manufacturing market. The company deals in manufacturing and marketing lentivirus and major players in the cell and gene therapy market. It operates in more than 140 countries and has long term agreements with major pharmaceutical companies such as Novartis, Orchard Therapeutics, and Sanofi. It develops products related to therapeutic areas including oncology, ophthalmology, and CNS disorders. The company has a strong product portfolio which focuses on addressing the needs of the customer.
Porter’s Five Forces Model
Michael Porter’s five forces model gives a framework that models the global viral vector manufacturing market, which is influenced by five forces. The strategic business managers, trying to create an edge over competitive firms in the global viral vector manufacturing market can utilize this model to comprehend better the industry connection in which the firm operates. The components of each of the forces and the degree or impact of each component in the context of the global viral vector manufacturing market have been broken down and analyzed.
Threat of New Entrants
The threat of new entrants is medium in the global viral vector manufacturing market. Any contract development and manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. However, the budget required for research and development of a product is high as compare to other industries. Viral vectors are highly specialized and manufactured to be used in gene therapy products and clinical trials. Moreover, the majority of the customers are using products of well-established brands and they are likely to prefer established brands over new market player due to quality concerns and to maintain the quality of final product, which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
The suppliers in the global viral vector manufacturing market are raw material manufacturers. There are various suppliers present in the global viral vector manufacturing market. Switching cost of these suppliers is low due to intense competition, and also the raw materials required for the manufacturing of viral vectors are easily used. Moreover, suppliers are likely to enter into long term partnerships with viral vector manufacturers. Due to the increasing research and development activities related to the gene therapy and entry of major pharmaceutical companies in the market a large number of customers are available.
Moreover, several suppliers are there to cater to the needs of the customers which lead to intense competition between the existing suppliers. However, the quality of product plays an important role in the industry as the viral vectors are used in the manufacturing of final products used in gene therapy. However, low-quality products are likely to damage the quality of the final product, and it can cause adverse effects. Hence, customers are selective about suppliers. Due to this, the overall bargaining power of suppliers in the global viral vector manufacturing market is low.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global viral vector manufacturing market. The market has a limited number of buyers and very few viral vector manufacturing companies to cater to the need of the buyers. However, the viral vector products are specialized and play an important role in gene therapy product manufacturing, and the buyers of the viral vectors are moderately inclined towards quality products manufactured by trusted companies. As the products are manufactured for gene therapy and clinical trials, there are limited substitutes available in the market. Also, most of the buyers are pharmaceutical companies and research organizations; they are likely to enter into the long-term agreements with the viral vector manufacturers for uninterrupted supply. Moreover, they can exert pressure on the manufacturers due to the low switching cost and intense rivalry in the market, which is responsible for the increased bargaining power of buyers.
Threat of Substitutes
The threat of substitutes in the global viral vector manufacturing market is low to moderate. Viral vector manufacturing is used in the development and manufacturing of gene therapy. There are limited options available in the market to serve the need of the customers and which eliminates the threat of substitute. However, the increasing research and development activities and demand for safer vectors are likely to provide new substitutes to the viral vectors. Also, the high degree of switching cost decreases the threat of substitutes. The overall threat of substitutes in the global viral vector manufacturing market is low to moderate.
Intensity of Rivalry
The rivalry in the global viral vector manufacturing market is moderate to high. The low degree of product differentiation and a limited number of customers increases the intensity of rivalry in the market. The market is growing with a prominent growth rate and likely to provide opportunities for major players to expand their geographical boundaries which will initiate cutthroat competition between major players to capture maximum market share in the emerging markets. Major players are trying to develop products under their own as a part of vertical integration. Players are engaged in developing a process to lower their manufacturing and logistics cost to increase profitability and to overcome the competition. Moreover, they are also developing advanced products for differentiating their brand from their competitors.
See plans for professionals or small and medium businesses.
Analytical insights on Viral Vector Manufacturing Market covering market dynamics, competitive landscape, and strategic outlook.
Viral Vector Manufacturing Market represents a significant market opportunity with multiple growth drivers across regions and segments.
The viral vector manufacturing market is entitled to witness profitable market growth during the forecast period of 2018 to 2023. Factors characterizing market growth are the rising worldwide prevalence of cancer, infectious diseases, and genetic disorders, ongoing research on viral vector-based gene and cell therapies, technological advancements in vector production, and increasing funding for R&D activities for the development of gene therapy. In contrast, high costs associated with the development of gene therapy treatment and challenges in viral vector manufacturing such as short shelf-life of viral vectors, possible risk of insertional mutagenesis, and immune barriers to successful gene therapy are likely to restrict market growth over the forecast period. On the other hand, the development of new synthetic gene-delivery vectors along with growing demand for synthetic genes and the presence of untapped opportunities in Asia-Pacific countries such as China, India, Australia, and Japan would create ample opportunities for new market entrants in the near future.
Various synthetic virology approaches are adopted to design AAV-based gene delivery vectors to obtain control over naturally encoded biomolecular programs already embedded in the AAV capsid which is facilitating the demand for synthetic genes. Viral vectors are efficient gene transfer tools. However, drawbacks, such as the bloodstream’s rapid clearance of viral vectors (when injected systemically) and their immunogenic and inflammatory potential, together with certain safety concerns, have driven the development of new synthetic gene-delivery vectors, thereby creating plenty opportunities for new market entrants and existing market participants.
High costs linked to gene therapy make it inaccessible to most patients. However, companies have sought extremely high prices for gene therapy products that reach to the market. The US FDA’s approval for Kymriah had met lifesaving potential of this therapy; however, but patients have concerns about its cost (USD 475,000), which is gradually limiting its adoption in the market. The cost of gene therapies currently ranges between USD 0.5 million and USD 1.5 million. The high cost of gene therapies has a negative effect on market growth as viral vectors represent a key gene therapy delivery method and are essential during the design and development of novel gene therapy procedures.
Pricing Analysis
Pricing is one of the most important factors for a product to survive in the market. The manufacturers should focus on the buying capacity of the consumer and manufacture cost-efficient products to achieve maximum profit or revenue or market share of the overall industry. Recent trends support that major companies are reducing the cost of their products to capture the maximum market share and to attract more customers. The reduced cost is enabling the large companies to attract the local market with their high quality which forces the small companies to reduce the price of their products to sustain the market. Average price of 1.0 mL Adeno-associated Vector(>1x1012 vg/mL) is around USD 450 which is high as compared to the price of 1.0 mL Adenovirus Vector, USD 430 for > 1x1012 vg/mL concentration.
There are various factors which influenced the investment opportunities in the global viral vector manufacturing market such as market potential, market growth, market competition, profitability, government regulation, demand for the products in the region, innovation, research & development, strategic collaboration, joint venture, accusation, licensing, franchising and cost of production.
Wantstats identified it could be a profitable investment opportunity for existing players and new entrants, to focus specifically on the development of innovative products as the demand for it is anticipated to increase in the coming years with increasing animal population. The existing players can enter into a strategic partnership with viral vector manufacturers and pharmaceutical companies to develop innovative and unique viral vectors which could be used for gene therapy. Currently, a number of companies are engaged in developing gene therapies for the treatment of rare disorders for which they have adopted strategic partnership strategies. Moreover, major players in the market are investing a large amount of revenue for increasing manufacturing capacities and expansion of the viral vector manufacturing business. For instance, in April 2017, Cobra Biologics announced the expansion of its gene therapy manufacturing unit in the UK and Sweden. This expansion will help the company to increase the viral vector manufacturing and catering to the increasing demand in the region.
Wantstats analysis revealed that the growing demand for advance veterinary animal vaccines products could pose huge opportunities for the companies in the market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 107 companies operating in the Viral Vector Manufacturing Market market, including revenue, employee count, and market positioning where available.
Showing 107 of 107 companies
Company Headquarters: Amsterdam, Netherlands Founded: 1998 Workforce: 200+ Company Working: uniQure N.V. is engaged in development, manufacturing, and marketing of gene therapy products in the Europe and Americas. The company offers innovative technology, manufacturing platforms, and finished products for the treatment of rare disorders such as hemophilia B, Huntington’s disease, hemophilia A, Fabry disease, and central nervous system disorders. The company offers preclinical services, provide support to the development of drugs, manufacturing and marketing of gene therapy products related to the liver/metabolic, central nervous system and other chronic disorders.
Company Headquarters: Cambridge, Massachusetts, US Founded: 2013 Workforce: 500+ Company Working: Brammer Bio is formed by the merger of Florida Biologix and Brammer Biopharmaceuticals.it is a prominent player in the global viral vector manufacturing market. The company is an experienced player in the contract development and manufacturing segment. The company has delivered more than 100 projects in the last 5 years and established collaboration with major clients to strengthen its position in the market. Brammer Bio offers end to solution to the biotechnology and pharmaceutical companies and has strong presence in the US. The company provides pre-clinical process and analytical development, process scale-up, process optimization, clinical and commercial supply of drug substances, process & analytical qualification, and formulated drug products.
Company Headquarters: Lyon, France Founded: 1995 Workforce: 1400+ Company Working: Novasep is a big name in molecule production and purification business and provides products and services to the life sciences and chemical companies. The company operates in business segments namely, pharmaceuticals, biopharmaceuticals, fine chemicals, agrochemicals, food ingredients, functional ingredients, and fermentation and chemical commodities. Moreover, the company offers contract development and manufacturing services to the other industry players. The company operates through its 11 manufacturing sites which are approved by Food and Drug Administration(US) and cGMP certification.
Company Headquarters: Kuopio, Finland Founded: 1997 Workforce: 100+ Company Working: FinVector Vision Therapies was previously known as Ark Therapeutics Limited and it is a major player in the market which is involved in research and development of viral-based gene therapy products. The company develops and manufactures products used for gene therapy through its manufacturing facility which is approved by European Medicines Agency(EMA). It offers services and viral-based product types, including Adenoviral, AAV, and Lentiviral-based vectors. The company operates in business segments namely, cell banking and viral seed stocks, R&D cell/gene therapy unit, platform process development / scale up, assay development and analytical testing, cGMP Manufacturing capabilities, FinVector aseptic filling capability, stability studies, Viral Vectors (including Adeno, AAV, Lenti), and Others.
Company Headquarters: Oxford, Oxfordshire, UK Founded: 1995 Workforce: 330+ Company Working: Oxford BioMedica is the first company to treat humans with the help of lentivirus and it is a leading player in the global cell and gene therapy market. The company develops and markets LentiVector technology which is widely used by physicians as a part of cell and gene therapy. The company operates in major markets in developed countries such as Americas and Europe. It has 20+ years’ experience in gene therapy segment and the company has conducted trials in more than 140 countries. The company has long term product related partnerships with major pharmaceutical players such as Novartis, orchard therapeutics, Sanofi, GlaxoSmithKline and has research and devleopmnet collaboration with Green Cross Labcell.
Company Headquarters: Keele, Northern Staffordshire, England Founded: 1992 Workforce: 201-500+ Company Working: Cobra Biologics was formerly known as RecipharmCobra Biologics Limited and operates as a subsidiary of Recip AB. it is a major player in the contract development and manufacturing (CDMO) segment which provides services such as pre-clinical, clinical, and commercial supply. The company operates in more than 18 counties and has manufacturing unit in Södertälje, Sweden. The company offers API services in pre-filled syringes, freeze drying/lyophilization, and injectable vial fill finish. It operates through DNA, viral vectors, technical proteins, microbiota, fill finish and other segments. The company has a strong research and development with more than 320 products in pipeline.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
